M Maurer Selected Research

Urticaria (Hives)

1/2022	Cold-induced urticaria associated with type I cryoglobulinemia, successfully treated with rituximab.
9/2020	Treatment of severe heat urticaria with omalizumab - report of a case and review of the literature.
1/2020	Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria.
1/2018	The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
1/2018	C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria.
1/2018	Development and validation of the Cholinergic Urticaria Quality-of-Life Questionnaire (CholU-QoL).
12/2017	Cholinergic urticaria patients of different age groups have distinct features.
6/2017	Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema.
12/2016	Atopic predisposition in cholinergic urticaria patients and its implications.
10/2016	Histamine intolerance in patients with chronic spontaneous urticaria.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Maurer Research Topics

Disease

38	Chronic Urticaria 06/2021 - 04/2004
26	Urticaria (Hives) 01/2022 - 02/2003
14	Angioedema 02/2019 - 11/2011
11	Pruritus (Itching) 11/2022 - 03/2005
11	Inflammation (Inflammations) 01/2020 - 08/2001
8	Hereditary Angioedemas 02/2019 - 07/2012
7	Hypersensitivity (Allergy) 06/2017 - 02/2003
5	Atopic Dermatitis (Atopic Eczema) 01/2020 - 08/2004
5	Cold Urticaria 03/2018 - 12/2007
5	Asthma (Bronchial Asthma) 07/2017 - 06/2006
4	Psoriasis (Pustulosis Palmaris et Plantaris) 11/2022 - 03/2015
4	Mastocytosis 01/2015 - 01/2010
4	Allergic Rhinitis 01/2015 - 06/2006
3	Chronic Inducible Urticaria 01/2021 - 01/2016
3	Familial dermographism 11/2019 - 07/2009
2	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 01/2013
2	Schnitzler Syndrome 01/2018 - 07/2012
2	Skin Diseases (Skin Disease) 12/2017 - 07/2009
2	Respiratory Hypersensitivity 07/2017 - 10/2015
2	Acquired angioedema 04/2017 - 01/2011
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/2015 - 01/2013
2	Multiple Sclerosis 12/2015 - 10/2008
2	Neoplasms (Cancer) 10/2014 - 01/2008
2	Vasculitis (Vasculitides) 06/2013 - 08/2007
2	Exanthema (Rash) 01/2013 - 12/2012
2	Cryopyrin-Associated Periodic Syndromes 12/2012 - 07/2012
1	Gastroesophageal Reflux (GERD) 05/2022
1	Cryoglobulinemia 01/2022
1	Mood Disorders (Mood Disorder) 01/2022
1	Drug Hypersensitivity (Drug Allergy) 12/2021
1	Hereditary Angioedema Types I and II 12/2021
1	Anaphylaxis (Anaphylactic Shock) 08/2020
1	Wound Infection (Wound Infections) 10/2019
1	Hidradenitis Suppurativa 01/2019
1	Hepatitis 10/2018
1	Asphyxia (Suffocation) 01/2018
1	Melanoma (Melanoma, Malignant) 01/2018

Drug/Important Bio-Agent (IBA)

16	Omalizumab (Xolair)FDA Link 01/2021 - 02/2011
15	Histamine Antagonists (Antihistamines)IBA 01/2020 - 01/2008
12	Immunoglobulin E (IgE)IBA 01/2020 - 02/2003
9	Histamine (Histamine Dihydrochloride)FDA Link 09/2019 - 04/2004
8	icatibantIBA 12/2021 - 01/2011
6	BradykininIBA 02/2019 - 11/2011
6	Cholinergic Agents (Cholinergics)IBA 01/2018 - 02/2008
6	Biomarkers (Surrogate Marker)IBA 01/2018 - 04/2009
5	Pharmaceutical PreparationsIBA 06/2017 - 01/2008
5	desloratadine (Aerius)FDA LinkGeneric 10/2012 - 04/2008
4	rupatadineIBA 01/2015 - 04/2008
3	AutoantibodiesIBA 06/2021 - 04/2004
3	Interleukin-6 (Interleukin 6)IBA 10/2019 - 07/2013
3	EnzymesIBA 01/2019 - 04/2009
3	AllergensIBA 07/2017 - 06/2006
3	miltefosine (Impavido)IBA 03/2013 - 01/2010
3	levocetirizine FDA LinkGeneric 10/2012 - 04/2009
3	Histamine H1 AntagonistsIBA 09/2010 - 07/2009
3	ebastine (Kestin)IBA 07/2009 - 12/2007
2	AntipruriticsIBA 11/2022 - 07/2009
2	CytokinesIBA 01/2020 - 01/2015
2	Interleukin-17 (Interleukin 17)IBA 01/2020 - 01/2015
2	SodiumIBA 01/2020 - 03/2010
2	Antiviral Agents (Antivirals)IBA 10/2018 - 10/2008
2	bilastineIBA 10/2018 - 07/2013
2	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 03/2005
2	fibrin fragment D (D-dimer)IBA 01/2018 - 01/2017
2	C-Reactive ProteinIBA 01/2018 - 01/2017
2	Vitamin D FDA LinkGeneric 01/2017 - 01/2015
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2017 - 04/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2016 - 08/2014
2	Complement System Proteins (Complement)IBA 02/2016 - 12/2000
2	anti-IgE antibodiesIBA 09/2015 - 06/2015
2	Interleukin-33IBA 01/2015 - 10/2014
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2013 - 07/2012
2	Interleukin-1 (Interleukin 1)IBA 12/2012 - 07/2012
2	fexofenadine (Allegra)FDA LinkGeneric 10/2012 - 07/2009
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 05/2022
1	Rituximab (Mabthera)FDA Link 01/2022
1	Lipoproteins (Lipoprotein)IBA 01/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 12/2021
1	Polysorbates (PSML)FDA Link 08/2020
1	mepolizumabIBA 08/2020
1	secukinumabIBA 01/2020
1	benralizumabIBA 11/2019
1	Dihydrotachysterol (AT 10)IBA 09/2019
1	Capsaicin (Zostrix)FDA Link 09/2019
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 02/2019
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 02/2019
1	Bradykinin B2 ReceptorIBA 01/2019
1	ImmunosorbentsIBA 01/2019
1	Plasma KallikreinIBA 09/2018
1	avoralstatIBA 09/2018
1	Kallikreins (Kallikrein)IBA 09/2018
1	Enterotoxins (Enterotoxin)IBA 07/2018
1	reslizumabIBA 03/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Fibrinogen (Factor I)FDA Link 01/2018
1	ProteomeIBA 01/2018
1	Diphenhydramine (Benadryl)FDA LinkGeneric 10/2017
1	Syk KinaseIBA 07/2017

Therapy/Procedure

16	Therapeutics 11/2022 - 01/2008
2	Injections 11/2013 - 01/2006